When was Enveda founded?

Enveda was founded in 2019 and became a unicorn in 2025.

Where is Enveda located?

Enveda is headquartered in Boulder, United States.

Who is the current CEO of Enveda?

Viswa Colluru of Enveda. They have also founded 1 company.

How many employees does Enveda have?

As of Aug 31, 2025, Enveda has 153 employees, reflecting a 27% year-over-year growth in headcount.

Is Enveda a funded company?

Enveda is a funded company, having raised a total of $517M across 11 funding rounds to date. The company's 1st funding round was a $150K Grant (prize money) round, raised on Jan 01, 2019.

How much is Enveda worth?

The latest valuation of Enveda is $1B as of Sep 04, 2025. This marks a decline of 24% from its peak valuation of $1.3B in Dec, 2022. This marks a decline of 24% from its peak valuation of $1.3B in Dec, 2022.

When was the latest funding round of Enveda?

Enveda's latest funding was a $150M Series D round on Sep 04, 2025, with participation from 12 investors. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $2.6B in funding in 2026 to date.

Is Enveda a Life Sciences Tech company?

The primary sectors of Enveda are Life Sciences Tech, Metabolic Diseases, Neurology, Obesity and Gastroenterology.

Where does Enveda rank among its competitors?

Enveda ranks 10th amongst 354 active competitors, of which 116 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Alto Neuroscience, which secured $120M in Mar, 2026.

Who are the top competitors of Enveda?

Enveda's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Adocia. Among them, Alto Neuroscience secured the most recent funding round in March, 2026.

Enveda - 2026 Company Profile, Team, Funding & Competitors

Sectors and market segments that Enveda operate in

Enveda serves in the HealthTech, Life Sciences market segments.The primary business model of Enveda are:

Company Details

AI-based platform to decipher the chemistry of nature and develop new medicines. It employs advanced computational methods, high throughput automation, and metabolomics to identify potential treatments for various diseases. It leverages chemical knowledge of nature to accelerate drug discovery and development.

Website: enveda.com
Social

Key Metrics

Founded Year

2019

Location

Boulder, United States

Stage

Series D

Total Funding

$517M in 11 rounds

Latest Funding Round

Series D, Sep 04, 2025, $150M

Post Money Valuation

$1B as on Sep 04, 2025

Investors

True Ventures & 30 more

Ranked

10^th among 354 active competitors

Employee Count

153 as on Aug 31, 2025

Similar Companies

Adocia & 355 more

View Enveda's full profile

Enveda is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
ENVEDA THERAPEUTICS INDIA PRIVATE LIMITED CIN: U73100AP2019FTC112638 , United States, Active	Aug 07, 2019	-	153 (As on Aug 31, 2025)	-

Enveda has raised a total funding of $517M over 11 rounds. Its first funding round was on Jan 01, 2019. Its latest funding round was a Series D round on Sep 04, 2025 for $150M. 12 investors participated in its latest round. Enveda has 27 institutional investors and 4 angel investors.

Here is the list of recent funding rounds of Enveda:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 04, 2025	$150M	Series D	$1B	-	Premji Invest	Baillie Gifford, Kinnevik, Lingotto, peakline.com, FPV Ventures, Dimension, Level Ventures, Henry Kravis, IA Ventures, Lux Capital, Socium Ventures
Feb 26, 2025	Undisclosed	Series C	-	-	-	Sanofi
Nov 21, 2024	$130M	Series C	-	-	Kinnevik, FPV Ventures	Baillie Gifford, Premji Invest, Lingotto, Lux Capital, Dimension, True Ventures, The Nature Conservancy, Henry Kravis, peakline.com

Access funding benchmarks and valuations. Sign up today!

View details of Enveda's funding rounds and investors

The founders of Enveda is Viswa Colluru. Viswa Colluru is the CEO of Enveda.

Here are the details of Enveda's key team members:

Viswa Colluru: Founder & CEO of Enveda.
Contact Info: 1 email address

View details of Enveda's Founder profiles and Board Members

Enveda's employee count trend

Enveda has 153 employees as of Aug 25. The total employee count is 26.0% more than what it was in Aug 24. Here is Enveda's employee count trend over the years:

Uncover Enveda's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Enveda include Rhythm Pharmaceuticals, MannKind Corp and Adocia. Here is the list of Top 10 competitors of Enveda, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
2nd	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Deerfield & 1 others	70/100
3rd	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
4th	Alto Neuroscience 2019, San Francisco (United States), Public	AI-driven drug discovery platform for neurological diseases based on patients biomarkers	$145M	Commodore Capital, Alkeon Capital Management ... & 36 others	68/100
5th	Corcept 1998, Menlo Park (United States), Public	Developer of cortisol modulators for the treatment of various diseases	-	Cornerstone Capital, BioBrit & 7 others	68/100
6th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, Sanofi & 5 others	65/100
7th	Quell 2019, London (United Kingdom), Series B	Developer of engineered regulatory T cell therapies for immune diseases	$344M	Syncona, Fidelity Investments & 17 others	64/100
8th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Smile Gate Investment, Praxis Capital & 10 others	64/100
9th	Rani Therapeutics 2012, San Jose (United States), Public	Developer of technology for the oral delivery of large drug molecules	$226M	Cathay Financial Holdings, Shire & 18 others	64/100
10th	Enveda 2019, Boulder (United States), Series D	AI-based platform to decipher the chemistry of nature and develop new medicines	$517M	Allen & Company, Baillie Gifford & 29 others	63/100